Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMRANASDAQ:GOVXNASDAQ:KZIANASDAQ:TFFP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMRAComera Life Sciences$0.00$0.00$0.00▼$0.03$6K0.779,936 shsN/AGOVXGeoVax Labs$0.90-0.6%$0.99$0.73▼$11.18$13.70M3.451.46 million shs694,752 shsKZIANovogen$6.59+7.9%$4.84$2.86▼$79.00$6.15M2.48384,112 shs42,139 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23N/A0.98896,182 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMRAComera Life Sciences0.00%0.00%+100.00%0.00%-99.20%GOVXGeoVax Labs-0.58%-3.02%-11.21%-29.39%-59.24%KZIANovogen+7.86%-26.04%+84.08%+38.74%-33.50%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-96.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AGOVXGeoVax Labs3.0253 of 5 stars3.64.00.00.02.01.70.6KZIANovogen3.7959 of 5 stars3.55.00.00.03.10.00.0TFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMRAComera Life Sciences 0.00N/AN/AN/AGOVXGeoVax Labs 3.29Buy$11.101,137.73% UpsideKZIANovogen 3.00Buy$57.50772.53% UpsideTFFPTFF Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KZIA, GOVX, TFFP, and CMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.004/16/2025GOVXGeoVax LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/15/2025GOVXGeoVax LabsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.504/10/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/28/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMRAComera Life Sciences$1.00M0.01N/AN/AN/A∞GOVXGeoVax Labs$3.95M3.45N/AN/A$0.48 per share1.87KZIANovogen$1.51M4.41N/AN/A($9.87) per share-0.67TFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMRAComera Life Sciences-$18MN/A0.00∞N/AN/AN/AN/AN/AGOVXGeoVax Labs-$24.99M-$3.65N/AN/AN/A-438.20%-511.96%-286.58%8/5/2025 (Estimated)KZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals-$21.24M-$6.44N/A∞N/A-1,596.64%-310.17%-196.06%N/ALatest KZIA, GOVX, TFFP, and CMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 million3/27/2025Q4 2024GOVXGeoVax Labs-$0.79-$0.30+$0.49-$0.30$2.38 million$3.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMRAComera Life SciencesN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMRAComera Life SciencesN/AN/AN/AGOVXGeoVax LabsN/A3.623.62KZIANovogenN/A0.21N/ATFFPTFF PharmaceuticalsN/A0.890.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMRAComera Life SciencesN/AGOVXGeoVax Labs6.09%KZIANovogen30.89%TFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipCMRAComera Life Sciences8.90%GOVXGeoVax Labs1.20%KZIANovogen1.00%TFFPTFF Pharmaceuticals4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableGOVXGeoVax Labs1015.19 million15.01 millionNot OptionableKZIANovogen121.01 million997,000OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableKZIA, GOVX, TFFP, and CMRA HeadlinesRecent News About These CompaniesTFF Pharmaceuticals approves dissolution planMarch 8, 2025 | uk.investing.comTFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC DeregistrationFebruary 6, 2025 | prnewswire.comTFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True PotentialDecember 12, 2024 | bovnews.comBThe TFFP Stock Mystery: Why Did TFFP Plunge Today?December 6, 2024 | bovnews.comBTFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?November 23, 2024 | bovnews.comBStock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?November 20, 2024 | bovnews.comBTFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock MovementsNovember 19, 2024 | bovnews.comBU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%November 15, 2024 | msn.comTFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?November 15, 2024 | bovnews.comBTFF Pharmaceuticals Shares Fall 66%; Company to Wind DownNovember 14, 2024 | marketwatch.comTFF Pharmaceuticals terminates employees, to wind down operationsNovember 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals to Dissolve and Liquidate AssetsNovember 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of OperationsNovember 14, 2024 | quiverquant.comQTFF Pharmaceuticals Announces It Will Wind Down OperationsNovember 14, 2024 | globenewswire.comTFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comTFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's WhyOctober 8, 2024 | zacks.comTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | finanznachrichten.deTFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | markets.businessinsider.comPost-COVID Trends in Biopharma Contract ManufacturingSeptember 25, 2024 | contractpharma.comCThe Yadot Group to Acquire Experiential Agency Socials DallasSeptember 16, 2024 | dallasinnovates.comDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKZIA, GOVX, TFFP, and CMRA Company DescriptionsComera Life Sciences NASDAQ:CMRA$0.0002 0.00 (0.00%) As of 06/24/2025Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.GeoVax Labs NASDAQ:GOVX$0.90 -0.01 (-0.58%) As of 06/25/2025 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Novogen NASDAQ:KZIA$6.59 +0.48 (+7.86%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$6.62 +0.03 (+0.46%) As of 06/25/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.TFF Pharmaceuticals NASDAQ:TFFP$0.06 0.00 (0.00%) As of 04/10/2025TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
